BLACKSBURG, VA — September 3, 2019 — Landos Biopharma,Inc.,today announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will present at the following conferences in New York:
Event: BioCentury 26th Annual NewsMakers in the Biotech Industry
Sept. 6, 2019 Location: Millennium Times Square
Date/Time: Friday, Sept. 6, at 9:20 a.m. EDT
Event: H.C. Wainwright 21st Annual Global Investment Conference, Sept. 8-10, 2019
Location: Lotte New York Palace Hotel
Date/Time: Tuesday, Sept. 10, at 3:50 p.m. EDT
Webcast: A live and archived webcast of the presentation will be available at http://wsw.com/webcast/hcw5/lans/.
About Landos Biopharma
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company has completed Phase 1 clinical testing and has initiated Phase 2 clinical testing of BT-11 for inflammatory bowel disease in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which Landos anticipates will advance to IND and Phase 1 clinical testing in 2020. Landos is headquartered in Blacksburg, Va. For more information, please visit www.landosbiopharma.com or contact firstname.lastname@example.org or follow us @Landosbio.
Chiara Russo (investors)
Rich Allan (media)